Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Autologous serum eye drops for dry eye.

ABSTRACT:

SUBMITTER: Pan Q

PROVIDER: S-EPMC5510593 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Autologous serum eye drops for dry eye.

Pan Qing Q Angelina Adla A Marrone Michael M Stark Walter J WJ Akpek Esen K EK

The Cochrane database of systematic reviews 20170228

<h4>Background</h4>Theoretically, autologous serum eye drops (AS) offer a potential advantage over traditional therapies on the assumption that AS not only serve as a lacrimal substitute to provide lubrication but contain other biochemical components that allow them to mimic natural tears more closely. Application of AS has gained popularity as second-line therapy for patients with dry eye. Published studies on this subject indicate that autologous serum could be an effective treatment for dry e ...[more]

PMID: 28245347

Similar Datasets

Autologous serum eye drops for dry eye.

Project description: Not available

| S-EPMC4007318 | biostudies-literature

Autologous serum eye drops for patients with dry eye disease: a systematic review and meta-analysis of randomized controlled trials.

Project description: Not available

| S-EPMC11427303 | biostudies-literature

MSCs-encapsulated porous microparticle eye drops for autoimmune dry eye disease treatment

Project description:Dry eye disease (DED) characterizes by chronic inflammation and an unstable tear film. Stem cells have shown potential for DED treatment, but the main challenge lies in improving the effectiveness of cell delivery. Here, we developed novel eye drops for DED treatment by employing porous microcarriers with mesenchymal stem cells. The microcarriers were created by electrospraying the solution of Arginine-Glycine-Aspartic Acid (RGD) peptides-modified sodium alginate with polyethylene oxide and mesenchymal stem/stromal cells (MSCs) into the calcium chloride solution. In vitro experiments based on a hyperosmotic corneal epithelial cell model indicated that porous microcarriers encapsulated with MSCs (RGD-Alg@MSCs) demonstrated notable enhancements in cell viability, reductions in apoptosis and reactive oxygen species (ROS), and diminished expression of pro-inflammatory cytokines. In the DED model using non-obese diabetic (NOD) mice, RGD-Alg@MSCs effectively enhanced tear production, promoted corneal healing, and alleviated inflammation. Additionally, RGD-Alg@MSCs modulated the immune environment in DED by inhibiting dendritic cell (DC) activation and suppressing Th17 differentiation in vitro, effectively disrupting the inflammatory feedback loop characteristic of DED. This immune modulation strategy was further validated through in vivo experiments, confirming its therapeutic potential. Thus, the designed MSCs-encapsulated porous microcarrier system can improve stem cell delivery and DED treatment efficiency.

2025-04-23 | GSE295017 | GEO

Allogeneic and autologous serum eye drops: a pilot double-blind randomized crossover trial.

Project description: Not available

| S-EPMC9544559 | biostudies-literature

Comparison of novel lipid-based eye drops with aqueous eye drops for dry eye: a multicenter, randomized controlled trial.

Project description: Not available

| S-EPMC4404875 | biostudies-literature

Anti-inflammatory effects of glycine thymosin β4 eye drops in experimental dry eye.

Project description: Not available

| S-EPMC7201140 | biostudies-literature

Efficacy of 100% autologous platelet-rich plasma and 100% autologous serum in dry eye disease: a randomised controlled trial.

Project description: Not available